Advances in Biomarkers for PCa Diagnostics and Prognostics-A Way towards Personalized Medicine

Int J Mol Sci. 2017 Oct 20;18(10):2193. doi: 10.3390/ijms18102193.

Authors

Carsten Stephan^{1

2}, Klaus Jung^{3

4}

Affiliations

¹ Department of Urology, Charité University Hospital, 10117 Berlin, Germany. carsten.stephan@charite.de.
² Berlin Institute for Urologic Research, 10115 Berlin, Germany. carsten.stephan@charite.de.
³ Department of Urology, Charité University Hospital, 10117 Berlin, Germany. klaus.jung@charite.de.
⁴ Berlin Institute for Urologic Research, 10115 Berlin, Germany. klaus.jung@charite.de.

Abstract

Prostate cancer (PCa) is, with an estimated number of 161,360 cases and 26,730 deaths in 2017, the most common malignancy in the USA [...].

Publication types

Editorial
Introductory Journal Article

MeSH terms

Biomarkers, Tumor / metabolism*
Humans
Male
Neoplasm Grading
Precision Medicine
Prognosis
Prostatic Neoplasms / diagnosis*
Prostatic Neoplasms / metabolism

Substances

Biomarkers, Tumor